Cytoplasmically Retargeted HSV1-tk/GFP Reporter Gene Mutants for Optimization of Noninvasive Molecular-Genetic Imaging  by Ponomarev, Vladimir et al.
Cytoplasmically Retargeted HSV1-tk/GFP Reporter Gene Mutants
for Optimization of Noninvasive Molecular–Genetic Imaging
Vladimir Ponomarev*, Michael Doubrovin y, Inna Serganova y, Tatiana Beresten y, Jelena Vider*,
Aleksander Shavrin*, Ludmila Ageyeva*, Julius Balatoni z, Ronald Blasberg y and Juri Gelovani Tjuvajev*,y
Departments of *Radiology and yNeurology, zRadiochemistry/Cyclotron Core Facility, Memorial Sloan Kettering
Cancer Center, New York, NY 10021, USA
Abstract
To optimize the sensitivity of imaging HSV1-tk/GFP
reporter gene expression, a series of HSV1-tk/GFP
mutantswas developedwith altered nuclear localization
and better cellular enzymatic activity, compared to that
of the native HSV1-tk/GFP fusion protein (HSV1-tk/GFP).
Several modifications of HSV1-tk/GFP reporter gene
were performed, including targeted inactivating muta-
tions in the nuclear localization signal (NLS), the
addition of a nuclear export signal (NES), a combination
of both mutation types, and a truncation of the first 135
bp of the native hsv1-tk coding sequence containing a
‘‘cryptic’’ testicular promoter and the NLS. A recombi-
nant HSV1-tk/GFP protein and a highly sensitive sand-
wich enzyme-linked immunosorbent assay for HSV1-tk/
GFP were developed to quantitate the amount of
reporter gene product in different assays to allow
normalization of the data. These different mutations
resulted in various degrees of nuclear clearance,
predominant cytoplasmic distribution, and increased
total cellular enzymatic activity of the HSV1-tk/GFP
mutants, compared to native HSV1-tk/GFP when ex-
pressed at the same levels. This appears to be the result
of improvedmetabolic bioavailability of cytoplasmically
retargeted mutant HSV1-tk/GFP enzymes for reaction
with the radiolabeled probe (e.g., FIAU). The analysis of
enzymatic properties of different HSV1-tk/GFP mutants
using FIAU as a substrate revealed no significant
differences from that of the native HSV1-tk/GFP. Im-
proved total cellular enzymatic activity of cytoplasmi-
cally retargeted HSV1-tk/GFPmutants observed in vitro
was confirmed by noninvasive imaging of transduced
subcutaneous tumorxenografts bearing these reporters
using [131I]FIAU and a ;-camera.
Neoplasia (2003) 5, 245–254
Keywords: molecular imaging; herpes virus type one thymidine kinase; green
fluorescent protein; FIAU; PET.
Introduction
Recent advances in noninvasive molecular imaging have
provided new research tools for monitoring the expression
of different genes and activities of various signal trans-
duction pathways. Reporter systems have been developed for
tracking transgene expression in vitro as well as in vivo, and in
transgenic animals. Reporter gene systems that are based on
enzymatic signal amplification include luciferase [10], herpes
virus 1 thymidine kinase (hsv1-tk) [45,47], cytosine deaminase
(CD) [24,44], uracil phosphoribosyl transferase (UPRT) [16],
xanthine phosphoribosyl transferase (XPRT) [39], and human
truncated mitochondrial thymidine kinase type two (DhTK2)
[38]. The fluorescent protein–based reporter gene systems
include Aequorea victoria green fluorescent protein (GFP) and
different spectral-shifted GFP variants [11,17,18,25], human-
ized version (hrGFP) [31,32], and red fluorescent proteins
(Red1 andRed2) [7,35]. Several bioluminescent reporter genes
are being widely used for whole body bioluminescent imaging in
animals such as Renilla and Firefly luciferase enzymes in
combination with their substrates coelenterazine and luciferine,
correspondingly [2,41]. The receptor-based systems include
dopamine receptor type 2 (D2R) [33], somatostatin receptor
(SSTr2) [42], and sodium iodide symporter (NIS) [23].
HSV1-tk is one of the most studied reporter genes for
noninvasive radionuclide imaging [21,26,45–47]. HSV1-tk
can phosphorylate different radiolabeled purine and pyrimidine
nucleoside analogs such as 2V-fluoro-2V-deoxy-1-h-D-arabino-
furanosyl-5-iodo-uracil (FIAU), 9-(4-[18F]fluoro-3-hydroxyme-
thylbutyl)guanine (FHBG), and other radiolabeled probes
[1,6,40,47]. Noninvasive radionuclide imaging of hsv1-tk
expression provides the opportunity to determine the location,
magnitude, and temporal dynamics of transgene expression
using g-camera, SPECT, or positron emission tomography
(PET) [21,45,47]. In previous reports, we described the
HSV1-tk/GFP fusion reporter gene, which combines the advan-
tages of hsv1-tk and GFP for monitoring gene transfer and
expression in vitro using fluorescent microscopy and FACS, as
well as in vivo using g-camera, SPECT, and PET [26].
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Recently, we extended the application of HSV1-tk/GFP
reporter gene to imaging the expression of various endoge-
nous genes and the activity of signal transduction pathways
[15,36].
The use of tissue-specific hsv1-tk gene expression in
transgenic mice for sensitization of these tissues to ganci-
clovir (GCV) treatment had limited success. This is due to the
presence of a putative cryptic testis-specific promoter within
the coding sequence of the hsv1-tk gene [9,43], which
renders the transgenic males sterile. The latter occurs
because of spermatozoal toxicity induced by high nuclear
concentrations of the HSV1-tk enzyme. The N-terminal
truncated variant of hsv1-tk has been shown to have no
spermatozoal toxicity in transgenic mice in the absence of
the cryptic testis-specific promoter. However, it was demon-
strated that N-terminal truncation of hsv1-tk results in the
attenuation of its enzymatic activity [9,43]. Degreve et al.
[13,14] described nuclear localization signal (NLS), which
targets the native HSV1-tk protein or its fusion with GFP to
the cell nucleus. The NLS in HSV1-tk protein is a nonapep-
tide (25-RRTALRPRR-33). In addition, the amino acids
R236-R237 and K317-R318 in the C-terminal portion of
HSV1-tk have also been shown to mediate the nuclear
tropism of HSV1-tk protein, its cell toxicity [12], and male
sterility in transgenic mice [9,43].
The aim of this study was to develop and evaluate a series
of HSV1-tk/GFP mutants with altered nuclear localization
and with better cellular enzymatic activity compared to that of
the native HSV1-tk/GFP fusion protein. We performed sev-
eral modifications of the native HSV1-tk/GFP reporter gene,
including targeted mutations in the NLS, the addition of a
nuclear export signal (NES), the combination of both muta-
tions, and the truncation of the first 135 bp of the native
hsv1-tk coding sequence that contains the cryptic testicular
promoter and the N-terminal NLS. These different mutations
resulted in various degrees of nuclear clearance and
predominant cytoplasmic distribution, as well as increased
total cellular enzymatic activity of the mutant HSV1-tk/GFP
variants compared to native HSV1-tk/GFP expressed at the
same levels. The improved total cellular enzymatic activity of
cytoplasmically retargeted HSV1-tk/GFP mutants was also
observed by noninvasive imaging of transduced subcutane-
ous tumor xenografts bearing these reporters.
Materials and Methods
Hsv1-tk/GFP Mutations and Expression Vectors
The schematic structures of the retroviral vectors used in
this study are shown in Figure 1. The retroviral vector SFG-
wt-HSV1-tk/GFP has been described previously [26]. A
mutation of two arginine residues (Arg25 and Arg26) into
corresponding glycine-25 and serine-26 residues within the
NLS of the native hsv1-tk sequence of the fusion gene was
achieved using the Quick-Change site-directed mutagenesis
kit (Stratagene, La Jolla, CA). To inactivate the NLS signal of
hsv1-tk, the codons for Arg25–Arg26 amino acids were
replaced by the BamHI restriction site, 5V-GGATCC-3V (to
encode Gly25–Ser26), by polymerase chain reaction
(PCR) using the sense primer 5V-GCAACGGATCCACGGC-
GTTGCGCCCTC-3V and the antisense primer 5V-TGGCC-
GCGAGAACGCGCAGCCTGGTCG-3V. PCR amplification
of the mutant primers was performed with the Pfu DNA
polymerase (Stratagene) and SFG-wt-HSV1-tk/GFP as a
template using a temperature cycle program (30 seconds at
95jC followed by 12 cycles of 30 seconds at 95jC, 1 minute
at 55jC, and 12 minutes at 72jC). The native plasmid was
inactivated by digestion with the DpnI restriction enzyme
(Stratagene). The Gly25–Ser26–containing mutant vector
was transfected into the competent DH5a Escherichia coli
(Invitrogen, Carlsbad, CA). Ampicillin-resistant colonies were
screened for mutant plasmids by BamHI digestion. The
resulting vector was termed SFG-mNLS-HSV1-tk/GFP.
In another HSV1-tk/GFP mutant, the leucine-rich NES
sequence of the MAPKK cDNA of Xenopus encoding 20
amino acids (32–51) was inserted into the N-terminus of
HSV1-tk/GFP between His9 and Ala10 using MluI restriction
site, resulting in the SFG-NES-HSV1-tk/GFP vector.
A third HSV1-tk/GFP mutant was produced by a combi-
nation of the mutagenic procedures in NLS and the addition
of NES as described above. The resulting vector was termed
SFG-NES/mNLS-HSV1-tk/GFP vector.
The truncated HSV1-tk/GFP mutant was obtained as
follows: the D45HSV1-tk cDNA lacking the first 45 amino
acids (135 nucleotides) of the original HSV1-tk was amplified
Figure 1. Schematic structures of retroviral vectors for mammalian
expression of the native and different HSV1-tk/GFP mutants: (A) native
HSV1-tk/GFP; (B) mNLS-HSV1-tk/GFP with mutations in the N-terminal
nuclear localization signal; (C) NES-HSV1-tk/GFP with the addition of the
nuclear export signal from MAPKK; (D) NESmNLS-HSV1-tk/GFP with a
combination of mutations in vectors (B) and (C); and (E) D45HSV1-tk/GFP
with truncation of N-terminal sequence encoding the first 45 amino acids of
the native protein.
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using primers 5V-ACTGCCATGGCTCCCACGCTAC-3Vand 5V-
CCATGGTGGCGACCGGTG-3V and subsequently cloned
between NcoI sites of the SFG-wt-HSV1-tk/GFP vector
replacing native HSV1-tk cDNA. The resultant vector was
named SFG-D45HSV1-tk/GFP.
For the production of the retroviral vectors for transduc-
tion of tumor cells, 10 Ag of the DNA of each vector-encoding
plasmid was transfected into the GPG29 packaging cell line
using the calcium phosphate method as previously
described [19]. The vesicular stomatitis virus G-protein
(VSV-G)–pseudotyped retroviral particles were used as
cell-free viral stocks for transduction.
The pET-29 vector (Novagen, Madison, WI) was used
to establish HSV1-tk/GFP protein expression in prokary-
otic cells. Briefly, HSV1-tk/GFP cDNA was amplified using
primers 5V-ACTGACTGCATATGGCTTCGTACCCCTG-3V
and 5V-ACTGACTGGGATCCTTACTTGTACAGCTC-3V and
cloned into the pET-29 vector between NdeI and BamHI
restriction sites. The resultant vector was named pET-29
HSV1-tk/GFP.
Transduction of Tumor Cells
The RG2 rat glioma cell line was kindly provided by Dr. D.
Bigner (Duke University Medical Center, Durham, NC).
RG2 cells were grown as monolayers in MEM supple-
mented with 10% fetal calf serum (FCS) in at 37jC in
humidified atmosphere with 5% CO2. The in vitro trans-
duction of RG2 cells with the retroviral vectors was accom-
plished by exposing the cell monolayers to a filtered
(0.45 Am) culture medium obtained from the vector producer
cells for 8 hours in the presence of polybrene (8 Ag/ml;
Sigma, St. Louis, MO).
Flow Cytometry and Fluorescent Microscopy
Retrovirally transduced RG2 cells were grown as bulk
cultures for 48 hours and subsequently sorted for positive
HSV1-tk/GFP expression using FACS (FACSVantage; Bec-
ton Dickinson, CA); the 488-nm excitation beam and 510-nm
emission filters were used. Subcellular localization of the
HSV1-tk/GFP protein in transduced tumor cells was visual-
ized by fluorescence microscopy (Nikon, Osaka, Japan)
using similar excitation and emission parameters.
Assessment of HSV1-tk/GFP mRNA Expression
The levels of HSV1-tk/GFP mRNA in transduced tumor
cells expressing different HSV1-tk/GFP protein mutants
were assessed using RP-PCR. Total RNA was isolated from
the transduced tumor cells using the RNAeasy kit (Qiagen,
CA). The HSV1-tk/GFP mRNA amplification was performed
using specific primer 5V-ATGGCTTCGTACCCCTG-3V (for
all mutants except D45HSV1-tk/GFP) or 5V-ATGGCTCC-
CACGCTACTG-3V (for D45HSV1-tk/GFP) and reverse pri-
mer 5V-AAGGTCGGCGGGATGAG-3V, and 2 Ag of total
RNA in a Single-Tube RT-PCR System (Stratagene). These
sets of primers amplify a 578-bp fragment of the wild-type
and mNLS-bearing HSV1-tk coding sequence (1–578), a
670-bp fragment of the NES-containing mutant hsv1-tk, and
a 450-bp fragment of the truncated D45HSV1-tk. The param-
eters of RT-PCR were: RT at 45jC for 30 minutes, then 25
cycles of denaturing at 94jC for 1 minute, primer annealing
at 58jC for 30 seconds, and extension at 72jC for 1 minute,
using the DNA Engine thermal cycler (MJ Research, Wal-
tham, MA). To normalize the level of TKGFP mRNA expres-
sion in different cell populations, rat GAPDH mRNA was
measured using the 5V-CAAGTTCAATGGCACAGTCAAG-3V
and 5V-TTGGCAGGTTTCTCCAGG-3V primers, which pro-
duced a 600-bp fragment.
HSV1-tk/GFP Protein Production and Purification
The plasmid pET-29HSV1-tk/GFP was transfected into a
strain of E. coli BL21(DE3) (Invitrogen) according to the
manufacturer’s protocol; bacteria in 800 ml of inoculated
media (with 100 Ag/ml carbenicillin) were incubated at
37jC with continuous shaking until an OD of 0.6 was
reached. Expression of HSV1-tk/GFP protein was induced
by adding IPTG (Sigma, St. Louis, MO) to a final concen-
tration of 1 mM. The incubation was continued until an OD of
1.2 was reached, and cells were harvested by centrifugation
at 15,000g for 20 minutes at +4jC. The bacterial pellet was
frozen at 80jC and stored until use. The cell pellet was
thawed on ice and homogenized in 35 ml of lysis buffer (100
mM NaH2PO4, 0.5 M NaCl, 8 M urea, pH 8.0). Lysozyme (1
mg/ml; Sigma) was added to the lysate and the suspension
was incubated at +4jC for 30 minutes with shaking, which
was followed by sonication (610 seconds, 80 W, on ice).
Benzoase (1 Al/ml; Novagen) and Protease Inhibitor Cocktail
III (2 Al/ml; Novagen) were added and the lysate was
incubated at room temperature for 3 hours, followed by
centrifugation at 15,000g for 30 minutes at +4jC. The super-
natant was filtered through a 0.45-AM filter (Pall, East Hills,
NY). Purification of the recombinant HSV1-tk/GFP protein
was performed using FPLC (BioLogic LP; Bio-Rad Labo-
ratories, Hercules, CA) and HiTrap affinity columns loaded
with Ni2+ (1 ml; Amersham Pharmacia Biotech, Piscat-
away, NJ) as follows: the bacterial cell lysate was applied
to the column and eluted at a flow rate of 1 ml/min. The
column was washed with the lysis buffer (see above)
using a gradient pH from 8.0 to 4.0. Different elution
fractions were collected and analyzed by Western blot
using anti–HSV1-tk monoclonal antibody (kindly provided
by Dr. W. Summers, Yale University, New Haven, CT) and
fractions containing pure HSV1-tk/GFP protein were iden-
tified and collected.
Assessment of the Integrity of Different HSV1-tk/GFP
Mutant Proteins
The protein integrity of different HSV1-tk/GFP mutants
was assessed usingWestern blot analysis. Total protein was
extracted from tumor cells transduced with native HSV1-tk/
GFP or with different HSV1-tk/GFP mutants using the lysis
buffer 10 mM Tris–HCl (pH 7.5), 1 mM DDT, 1 mM EDTA,
20% glycerol, protease inhibitor cocktail (cat no. 8340;
Sigma) 150 AL/100 mL buffer, and ultrasonication at 4jC.
The lysate was centrifuged for 10 minutes at 5000 rpm, and
the protein concentration in supernatants was assayed
spectrophotometrically at 595 nm (UV-1201S; Shimadzu,
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Columbia, MD) using protein assay kit (cat no. 5000006; Bio-
Rad, Hercules, CA). The proteins were resolved by electro-
phoresis in 10% acrylamide gel and transferred to the
Immobilon-P membrane (Millipore, Bedford, MA) using a
dry transfer apparatus Mini-PROTEAN 3 (Bio-Rad Labora-
tories). The HSV1-tk/GFP proteins were detected using a
monoclonal anti-GFP antibody (cat no. 8362; Clontech, Palo
Alto, CA) at a 1:500 dilution or an anti–HSV1-tk monoclonal
antibody at 1:500 dilution and a secondary peroxidase anti-
mouse antibody (cat no. PI-2000; Vector Laboratories, Bur-
lingame, CA) at a 1:4000 dilution. Detection was performed
using an ECL Western blot detection kit (cat no. RPN 2106;
Amersham Pharmacia Biotech).
Sandwich enzyme-linked immunosorbent assay (ELISA) for
HSV1-tk/GFP Proteins
Anti-GFP Coated Clear Strip Plate (Pierce, Rockford, IL)
was used for HSV1-tk/GFP fusion protein detection in cell
lysates. The plate was washed with PBS containing 0.05%
Tween 20 (PBST) five times. Then, the plate was incubated
for 1 hour at room temperature either with 100 Al of recombi-
nant HSV1-tk/GFP protein serially diluted in PBS with 1%
BSA (to produce a reference standard curve), or with 100 Al of
sample (cell lysate, diluted in PBS with 1% BSA). Then, the
plate was washed five times with PBST and incubated with
100 Al of anti–HSV1-tk mAb (diluted at 1:200 in PBS with 1%
BSA, kindly provided by Dr.W. Summers, Yale University) for
1 hour at room temperature. Then, the plate was washed five
times with PBST and incubated with 100 Al of HRP-conju-
gated goat antimouse IgG+A+M (H+L) secondary antibody
(Zymed Laboratories, South San Francisco, CA) diluted at
1:2000 in PBS with 1% BSA for 1 hour at room temperature,
washed with PBST five times, and incubated for 20 minutes
with 100 Al of substrate reagent (1:1 mixture of H2O2 and
tetramethylbenzidine; R&D Systems, Minneapolis, MN). The
fluorochrome development reaction was stoppedwith 50 Al of
2 NH2SO4 and the absorbancewasmeasured at 450 nmwith
wavelength correction at 570 nm using plate reader Saphire
(TECAN, Salzburg, Austria). The concentration of HSV1-tk/
GFP protein in samples was calculated based on the stand-
ard curve obtained with the purified recombinant HSV1-tk/
GFP protein and expressed as micrograms per milligram of
total protein in transduced cells.
HSV1-tk In Vitro Enzymatic Assay
Different tumor cell lines stably transduced with various
mutant forms of HSV1-tk/GFP were grown until confluence in
15-cm tissue culture dishes (Nunc, Naperville, IL) in MEM
supplemented with 10% FCS in at 37jC in humidified
atmosphere with 5% CO2. The cells were wash with 10 ml
of sterile PBS and harvested by scraping in 10 to 15 ml of
PBS, and the cell pellet was obtained by centrifugation at
4jC for 10 minutes. The cell pellet was transferred into a
preweighed 1.5-ml vial to determine cell pellet weight (usu-
ally f20–30 mg/plate) and resuspended in 500 Al of lysis
buffer (10 mM Tris–HCl, pH 7.5, 1 mM DTT, 1 mM EDTA,
20% glycerol, 150 Al of Sigma protease inhibitor cocktail in
100 ml of buffer). The cell pellet was lysed by ultrasonication
on wet ice and centrifuged at 4jC for 10 minutes, and the
supernatant was transferred to another vial.
The assay was initiated bymixing 150 AL of cell lysate with
750 AL of assay buffer (Tris–HCl 150 mM, pH 7.5, ATP 10
mM, MgCl210 mM, NaF 25 mM, h-mercaptoethanol 10 mM)
containing 0.01 mM [14C] FIAU (Moravek Biochemicals,
Brea, CA) adjusted to 0.1 ACi/ml, and incubated at 37jC.
After 20, 40, 60, 90, 120, and 150 minutes, a 50-Al aliquot of
the reaction mixture was removed and spotted on a filter
paper DE81 (Whatman, Newton, MA), which was air-dried
for 2 minutes and then washed with 10 ml of H2O followed by
10 ml of 95% ethanol. The phosphorylated nucleoside (e.g.,
[14C]FIAU) was selectively retained on the filter paper after
these washes. The FIAU-MP radioactivity retained on the
filters was measured by h-spectroscopy (TriCarb 1600;
Packard, Billerica, MA) after the addition of solubilizer
Soluene (Packard) and scintillation cocktail Instafluor III
(Packard). To determine the total radioactivity in the aliquot
(FIAU+ FIAUMP), 50 Al of the reaction mixture was spotted
onto the filter paper and the radioactivity was measured
without washing the filter. The nonspecific binding of
[14C]FIAU to the filter paper was assessed by spotting
the reaction mixture containing a nontransduced tumor cell
lysate or no lysate at all followed by the regular washes.
The FIAU-MP–specific fraction of radioactivity in the reac-
t ion mixture was calculated as: [(washed sam-
plenonspecific binding)/total reaction sample] multiplied
by the initial FIAU concentration (0.01 mM). The MP-
specific fraction was plotted versus time and the apparent
rate of the reaction was assessed by fitting the data to
single-site binding equation using PRIZM v. 3.02 software
(GraphPad Software, San Diego, CA). The reaction rate
(AM FIAU/sec) was normalized to enzyme concentration
(AM HSV1-tk), which was measured by ELISA in a sample
obtained from the corresponding cell lysate.
FIAU Accumulation Assay
The FIAU accumulation assays were performed as pre-
viously described [47]. The cells were seeded in 15025-mm
tissue culture plates (Nunc) at a concentration of 1106
cells/plate and grown until 50% to 60% confluent. The
incubation medium was replaced with 14 ml of medium
containing 0.01 ACi/ml (56 mCi/mmol) [2-14C]FIAU and
0.2 ACi/ml (60 Ci/mmol) [met-3H]TdR (Moravek Biochemi-
cals). Radiochemical purity of each compound was checked
in our laboratory using HPLC and found to be >98%. The
cells were harvested by scraping after various periods of
incubation (10, 30, 60, 90, and 120 minutes) and centrifuged,
then cell pellets were weighed and assayed for radioactivity
concentration using a TriCarb 1600 h-spectrometer (Pack-
ard) using standard 3H and 14C dual-channel counting tech-
niques. The medium was also counted before and after
incubation. The data were expressed as a harvested cell-
to-medium concentration ratio: (dpm/g cells)/(dmp/ml
medium). The rates of accumulation (Ki) for FIAU and TdR
were determined from the slope of the cell-to-medium ratios
versus incubation time plots and have units of tracer clear-
ance from the medium (ml medium/min per g cells). The ratio
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of Ki values (the FIAU/TdR ratio) is a measure of HSV1-tk
activity and correlates with independent measures of the
gene expression [47].
Subcutaneous Tumors and Study Groups
The experimental protocol involving animals was
approved by the Institutional Animal Care and Use Commit-
tee of the Memorial Sloan Kettering Cancer Center. The
wild-type RG2 cells and transduced RG2 cells expressing
different types of mutant HSV1-tk/GFP gene were released
from the culture plates by treatment with 0.5% trypsin in PBS
for 5 to 10 minutes, resuspended in the growth media to
neutralize the trypsin, centrifuged to obtain the cellular pellet,
and then resuspended in MEM (without FCS) at a concen-
tration of 106 viable cells in 100 Al. Tumor cells (106 cells in 100
Al) were injected subcutaneously into rnu–rnu rats (Harlan
Sprague–Dawley, Indianapolis, IN), weighing 200 to 250 g.
Five subcutaneous tumors were produced in each rat,
including the wild-type RG2 tumor and four different trans-
duced TKGFP/RG2 tumors (wt-HSV1-tk/GFP/RG2, NES-
HSV1-tk/GFP/RG2, mNLS-HSV1-tk/GFP/RG2, and
NESmNLS-HSV1-tk/GFP/RG2), by injection of 106 cells
subcutaneous into five different sites. The transduced
tumors were produced in the dorsal aspects of both
shoulders, and into the right thigh and flank. The native
RG2 tumor was produced in the left flank and served as a
negative control.
No-Carrier-Added Synthesis [131I]FIAU and g-Camera
Imaging
No-carrier-added [131I]FIAU with >97% radiochemical
purity was prepared by the iododestanylation reaction using
the tin precursor and carrier-free 131I, followed by isolation of
the product by column chromatography as previously
described [47]. The specific activity of [131I]FIAU was esti-
mated to be more than 30 Ci/Amol. One day before
[131I]FIAU administration, the animals received an intraper-
itoneal injection of 0.9% NaI solution (1 ml) to block the
thyroid uptake of radioactive iodide (low amounts of which
develop by radiolysis). [131I]FIAU (300 ACi per animal) was
injected intravenously and 24 hours later, g-camera imaging
was performed on a Vertex dual-headed g-camera (ADAC,
Milpitas, CA) equipped with a high-energy high-resolution
(HEHR) collimator. Planar images were obtained and recon-
structed to 512512 matrix with 1.21.2-mm pixel size.
Statistics
Descriptive statistics of group data were performed
using univariate analysis. Group data were compared
using ANOVA analysis, regression analysis, and Student’s
t-test; a P value of <.05 was considered significant.
Statistical analysis of data was performed using the Stat-
View 4.57 (Abacus Concepts, Piscataway, NJ) and Kalei-
daGraph 3.5 (Synergy, Reading, PA).
Results
Subcellular Localization of Different Mutant HSV1-tk/GFP
Fusion Proteins
Fluorescent microscopic analysis of transduced tumor
cells demonstrated distinct differences in subcellular local-
ization of native andmutant HSV1-tk/GFP proteins. The wild-
type HSV1-tk/GFP localized predominantly to the cell
nucleus (Figure 2A). The mNLS-HSV1-tk/GFP and
D45HSV1-tk/GFP proteins exhibited pancellular distribution
with no visible differences between the nucleus and cyto-
plasm (Figure 2, B and E). The distribution of NES-HSV1-tk/
GFP and NESmNLS-HSV1-tk/GFP proteins was predomi-
nantly cytoplasmic, and the cell nuclei were dark and non-
fluorescing, indicating that the NES is functional (Figure 2C).
Notably, the double mutant NESmNLS-HSV1-tk/GFP protein
distribution exhibited an improved nuclear clearance com-
pared to NES-HSV1-tk/GFP protein (Figure 2D).
HSV1-tk/GFP Protein Expression in Transduced Cells by
RT-PCR and Western Blot
The RT-PCR–amplified fragments of wt-HSV1-tk/GFP
and mNLS-HSV1-tk/GFP mRNA had lengths of 578 bp and
the NES-HSV1-tk/GFP and NESmNLS-HSV1-tk/GFP
mRNA fragments had lengths of 648 bp. The length of
D45HSV1-tk/GFP was expectedly shorter, 443 bp. The
larger size of the NES-HSV1-tk/GFP and NESmNLS-
HSV1-tk/GFP mRNA fragments reflects the addition of a
Figure 2. Fluorescent photomicrographs of RG2 cells expressing the native and different HSV1-tk/GFP mutants: (A) native HSV1-tk/GFP; (B) mNLS-HSV1-tk/GFP
with mutations in the N-terminal nuclear localization signal; (C) NES-HSV1-tk/GFP with the addition of the nuclear export signal from MAPKK; (D) NESmNLS-
HSV1-tk/GFP with a combination of mutations in vectors (B) and (C); and (E) D45HSV1-tk/GFP with truncation of N-terminal sequence encoding the first 45 amino
acids of the native protein.
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sequence encoding the NES (Figure 3A). The native and full-
length mutant HSV1-tk/GFP proteins had the predicted
molecular mass of about 69 to 72 kDa, whereas the trun-
cated D45HSV1-tk/GFP was about 64 kDa, as determined
by Western blot analysis. The native and mutant HSV1-tk/
GFP proteins had similar stability and exhibited only a
minimal degree of degradation (Figure 3, B and C). These
results may be somewhat different in other tumor cell lines.
Enzymatic Properties of Different HSV1-tk/GFP Mutant
Proteins
The enzymatic properties of different HSV1-tk/GFP pro-
teins were assessed in vitro using whole cell lysates of
transduced tumor cells and the results are summarized in
Table 1. The enzyme concentration–normalized apparent
reaction rates observed with FIAU and different HSV1-tk/
GFP mutants were fairly similar.
FACS and Radiotracer Assessment of Mutant HSV1-tk/GFP
Protein Expression
The levels of enzymatic activity of the cytoplasmically
retargeted mutant HSV1-tk/GFP proteins (mNLS-HSV1-tk/
GFP, NES-HSV1-tk/GFP, NESmNLS-HSV1-tk/GFP, and
D45HSV1-tk/GFP) were assessed by FACS and the FIAU
accumulation assay in populations of transduced RG2 cells
with different levels of expression for each of the mutant
TKGFP variants. These different populations of cells were
selected on the basis of different levels of fluorescence as
measured by FACS. Different levels of native HSV1-tk/GFP
expression in tumor cell populations were achieved by mix-
ing transduced and nontransduced tumor cells in various
proportions; the native HSV1-tk/GFP fluorescence in the
resulting populations was also measured by FACS and
was found to correlate with the percentage of native HSV1-
tk/GFP cells in the population. The levels of HSV1-tk/GFP
fluorescence in different native HSV1-tk/GFP/nontrans-
duced cell mixtures and in various transduced cell lines
expressing different HSV1-tk/GFP mutant proteins corre-
lated with the concentrations of HSV1-tk/GFP (HSV1-tk/
GFP, Ag/mg total cellular protein) in corresponding cell
populations as measured with ELISA (Figure 4; R=0.89,
P< .0001, paired Student’s t-test).
Figure 3. Detection and analysis of the native and different HSV1-tk/GFP
mutants in transduced RG2 cells: (A) RT-PCR analysis; (B) Western blot
using a monoclonal anti –HSV1-tk antibody; and (C) Western blot using a
monoclonal anti-GFP antibody. Native—wt-HSV1-tk/GFP; with mutations in
the N-terminal nuclear localization signal—mNLS-HSV1-tk/GFP; with the
addition of the nuclear export signal from MAPKK—NES-HSV1-tk/GFP; with
both the NLS mutations and the addition of NES from MAPKK—NESmNLS-
HSV1-tk/GFP; with truncation of N-terminal sequence encoding the first 45
amino acids of the native protein—D45HSV1-tk/GFP.
Table 1. Comparison of Enzymatic Activities of Different HSV1-tk/GFP
Mutants In Vitro.
Reporter Protein Type Enzyme Activity (sec1)*
NES-HSV1-tk/GFP 4.44F0.58
D45HSV1-tk/GFP 1.94F0.13
mNLS-HSV1-tk/GFP 2.19F0.10
NESmNLS-HSV1-tk/GFP 1.22F0.89
Native HSV1-tk/GFP 2.04F0.70
*The apparent rate of the reaction normalized by the enzyme concentration
(AM FIAU/sec per AM HSV1-tk or sec1). The concentration of FIAU was
0.01 mM.
Figure 4. Relationship between two measurements of HSV1-tk/GFP
expression—FACS measurement of GFP fluorescence (mean value) and
ELISA assay of HSV1-tk/GFP protein levels. Strong linear relationship was
observed in corresponding cell populations (paired t-test, P < .001).
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The relationship between GFP fluorescence and FIAU
accumulation is shown in Figure 5. The FIAU/TdR normal-
ized accumulation ratios (enzymatic activity of the HSV1-tk
subunit) were similar in tumor cell populations expressing
different mutant HSV1-tk/GFP proteins. To increase the
statistical significance of the analysis, the data from tumor
cell populations expressing different mutant HSV1-tk/GFP
proteins were grouped together and the slope of the relation-
ship (1.3E4F3.8E5) was determined. This was very
similar to the value obtained in cell populations expressing
different levels of the native HSV1-tk/GFP protein
(1.5E4F2.4E5). Based on the ratio of Y-intercepts of
the slopes in Figure 5, the magnitude of the FIAU/TdR
accumulation ratio in various populations of tumor cells
expressing different levels of mutant HSV1-tk/GFP proteins
was roughly two-fold higher than that measured in popula-
tions of cells expressing different levels of native HSV1-tk/
GFP protein.
Imaging Expression of Different HSV1-tk/GFP Proteins by
g-Camera Imaging In Vivo
g-Camera imaging studies were performed in rats bearing
multiple subcutaneous tumors grown from transduced RG2
cell populations expressing the wt-HSV1-tk/GFP protein or
different mutant HSV1-tk/GFP proteins at similar levels.
These populations are identified as the outlined (dotted
cluster) in Figure 6. The nontransduced RG2 tumor served
as a negative control. Highly specific localization of
[131I]FIAU-derived radioactivity in tumors expressing the
native and mutant TKGFP proteins was seen (Figure 6A).
The levels of [131I]FIAU radioactivity in control (nontrans-
duced) RG2 tumors were very low and similar to body
background.
The highest levels of [131I]FIAU accumulation were
observed in tumors expressing the mNLS-HSV1-tk/GFP
and NES/mNLS-HSV1-tk/GFP protein 0.57F0.06% ID/g
and 0.57F0.09% dose/g, respectively (Figure 6B). Some-
what lower levels of [131I]FIAU radioactivity were observed in
NES-HSV1-tk/GFP tumors, 0.41F0.05% ID/g, and lower
levels of [131I]FIAU radioactivity were observed in tumors
expressing the wt-HSV1-tk/GFP protein, 0.31F0.05% ID/g.
Overall, the levels of [131I]FIAU accumulation in tumors
expressing mutant HSV1-tk/GFP proteins were about
two-fold higher than in those expressing the wt-HSV1-
tk/GFP protein.
Discussion
The objective of this study was to show that specific muta-
tions in the HSV1-tk/GFP reporter gene result in improved
imaging characteristics and improved sensitivity using
established radiolabeled probes. We demonstrate that tar-
geted mutations of HSV1-tk/GFP reporter protein designed
to overcome or disrupt its NLS lead to a wider subcellular
distribution of the mutant HSV1-tk/GFP proteins, and result
in improved total cellular enzymatic activity. The observed
improvements in functional imaging characteristics of
mutant HSV1-tk/GFP proteins did not result from an
enhancement of their enzyme kinetic properties with respect
to phosphorylation of radiolabeled probe, FIAU, which was
the preferred substrate for our studies [46]. The enzyme
kinetic studies performed with extracts of cells transduced
with either the native or different HSV1-tk/GFP mutants
demonstrated similar apparent rates of FIAU phosphoryla-
tion by these different enzymes at a concentration of FIAU
that was significantly greater than thef2 AM Km of FIAU for
HSV1-tk (Dr. K. Watanabe, personal communications). The
mutation in NLS results in pancellular and proportionally
more cytoplasmic localization of the mNLS-TG protein com-
pared to the wild-type TG. Further addition of NES into the
NESmNLS-TG was intended to completely clear the cell
nucleus from this protein. Therefore, the amount of residual
mNLS-TG protein in the nucleus is relatively low, as docu-
mented by virtually no gain of total cellular enzymatic activity
upon its clearance into the cytoplasm (in form of NESmNLS-
TG protein). Our data suggest that the increase in accumu-
lation of FIAU in cells transduced with cytoplasmically
retargeted HSV1-tk/GFP mutants occurs because cytoplas-
mic retargeting results in improved bioavailability of these
mutant enzymes for FIAU compared to the native HSV1-tk/
GFP enzyme (which has a nuclear localization). This expla-
nation is also supported by in vitro data (Figure 5), which
demonstrate a higher accumulation of FIAU in cells trans-
duced with cytoplasmically retargeted HSV1-tk/GFP
Figure 5. A comparison of expression levels of the native (open circles) and
different HSV1-tk/GFP mutants (closed squares) based on GFP domain
fluorescence with their ability to accumulate FIAU in transduced RG2 cells.
To achieve different levels of the native HSV1-tk/GFP expression levels, the
transduced RG2 cells were mixed with nontransduced cells in percentages
indicated on the plot above open circles. The data for HSV1-tk/GFP mutants
were grouped together and reflect multiple populations of transduced RG2
cells with different levels of mutant HSV1-tk/GFP expression. The data sets
for the native and different HSV1-tk/GFP mutants were fitted with a linear
function to assess the relationship. The cell populations with similar levels of
transgene expression (dotted rectangle) were later used to produce
subcutaneous tumors for the in vivo imaging studies.
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mutants compared to native HSV1-tk/GFP transduced cells
when the expression levels of the gene product (amount of
enzyme) are similar or normalized. It is noteworthy that the
expression levels of HSV1-tk/GFP in transduced cells were
assessed using two independent methods—FACS (GFP
subunit fluorescence) and a newly developed sandwich
ELISA for HSV1-tk/GFP fusion protein measurement.
Analysis of the crystal structure of native HSV1-tk enzyme
bound to different substrates [5,8,48] has demonstrated that
the N-terminal pole of the parallel h-sheet (containing the
N-terminus of the polypeptide) forms a part of the molecular
surface, but is not involved in the formation of the enzyme
catalytic site. As demonstrated in the current study, muta-
tions within the N-terminus or removal of a large portion of
the N-terminus (the first 45 amino acids) of the native HSV1-
tk did not impact on the enzymatic characteristics of cyto-
plasmically retargeted mutant HSV1-tk/GFP proteins. These
results are confirmatory of previous reports, which also
demonstrated that truncation of the first 34 N-terminal amino
acids or mutation of different Arg residues within this region
resulted in pancellular distribution of HSV1-tk/GFP chimeras
[14]. The retention of enzymatic activity of HSV1-tk after
truncation of the first 45 amino acids was demonstrated
previously using a GCV sensitivity assay in tumor cells
transduced with the N-terminally truncated HSV1-tk gene
[43], although no enzyme kinetic studies had been per-
formed in these studies [14,43].
Enzyme kinetic studies were performed in Q125, T63,
A168, R176, and C336 site-directed mutants of HSV1-tk to
clarify the contribution of these residues to the binding of
deoxyribose-containing or acycloanalogues of thymidine,
Mg2+, and ATP [30]. It was demonstrated that the Q125L
mutant is able to phosphorylate only thymidine, whereas the
Q125N mutant accepts both thymidine and acyclovir (ACV)
as substrates, and the Q125E mutation results in an
abolition of phosphorylation activity of the enzyme. T63
appears to be essential for the binding of Mg2+ and thus
the catalytic activity of the enzyme, whereas A168 limits
steric accessibility and, if mutated to a bulkier residue, will
exclude binding of larger substrate analogues. R176
appears to be essential for electrostatic balance within the
active site, and C336, which is located at the surface of TK
and directed toward the ATP binding site, disrupts the
three-dimensional structure of the whole active site by
shifting the LID domain.
Seminal studies by Black et al. [3,4], Kokoris and Black
[27], and Kokoris et al. [28,29] further identified the role of
different amino acids in substrate specificity of HSV1-tk.
Using random sequence and targeted mutagenesis
approaches, these researchers have produced numerous
mutant HSV1-tk enzymes with improved specificity towards
different acycloguanosine analogues, including GCV, ACV,
and pencyclovir (PCV) [3,4,27–29]. One of such mutant
enzymes, sr39TK, was extensively studied as a reporter
gene for noninvasive imaging with PET using different radio-
labeled acycloguanosine analogues as reporter probes,
including 8-[18F]GCV [20], [18F]FHPG [6,46], and [18F]FHBG
[46,49]. The results of these studies are complimentary to
those reported here because the mutations we introduced
into the HSV1-tk sequence of the HSV1-tk/GFP fusion
reporter gene were quite distant from the catalytic site of
the enzyme and, therefore, did not significantly impact on
substrate specificity or enzyme kinetics.
Figure 6. c-Camera imaging of [131I]FIAU accumulation in rats bearing
multiple subcutaneous tumors produced from RG2 cells expressing native
HSV1-tk/GFP or different HSV1-tk/GFP mutants at similar levels based on
GFP expression (see dotted cluster box in Figure 5) and from nontransduced
RG2 cells (panel A). The levels of [131I]FIAU accumulation measured in tissue
samples are expressed as percent injected dose per gram of tissue (panel B).
Paired t-test of FIAU accumulation in tumors expressing different mutant
HSV1-tk/GFP proteins versus tumors expressing native HSV1-tk/GFP protein
(n = 6, *P < .05, **P < .01).
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Following our initial reports on HSV1-tk/GFP mutagene-
sis described in the current paper [37], specific mutations in
sr39HSV1-tk were performed in arginines (R) 25 and 26 to
glycine (G) and serine (S), respectively, to create mNLS-
sr39HSV1-tk/GFP reporter gene to image two-protein inter-
actions, p53 and SV40, in living animals using [18F]FHBG
and PET [34]. The sr39HSV1-tk/GFP was reported to local-
ize predominantly in the nucleus of transiently transfected
HeLa cells. Conversely, the mNLS-sr39HSV1-tk/GFP was
distributed more uniformly in both the nucleus and cytosol,
consistent with disruption of one NLS. In the latter study, it
was also reported that the accumulation of a radiolabeled
nucleoside analog [8-3H]PCV in HeLa cells transiently trans-
fected with mNLS-sr39HSV1-tk was more than two-fold
greater than HSV1-sr39HSV1-tk and 12-fold greater than
native HSV1-tk, which is in accord with the results obtained
in our current studies.
It is known that the nuclear tropism of native HSV1-tk
causes cell toxicity when the enzyme is expressed at high
levels [9,43] and limits the expression level of this transgene.
In contrast, bulk populations of cells transduced with cyto-
plasmically retargeted HSV1-tk/GFP mutants consistently
exhibited higher levels of the transgene expression com-
pared to cells transfected with the native HSV1-tk/GFP using
the same vector backbone and promoter sequences. The
latter phenomenon is consistent with reduced nuclear toxicity
of cytoplasmically retargeted HSV1-tk/GFP mutants and the
absence of a nonspecific feedback inhibition of transgene
expression. Furthermore, it has been demonstrated that the
N-terminal truncated variant of HSV1-tk does not cause
spermatozoal toxicity in transgenic mice due to the removal
of cryptic testis-specific promoter sequences and of nuclear
localization–associated toxicity [12]. Therefore, if should be
feasible to use cytoplasmically retargeted or N-terminal–
truncated HSV1-tk/GFP reporter gene mutants for gen-
eration of transgenic mice bearing various reporter systems.
It is noteworthy that noninvasive imaging of the albumin
promoter-driven expression of the wild-type HSV1-tk
reporter gene (AL-HSV1-tk) in heterozygous transgenic mice
has been reported using 18F-FHBG and PET [22]. The AL-
HSV1-tk transgenic mice had been developed from FVB/N
mice by pronuclear injection, although no information was
provided regarding the fertility status of these AL-HSV1-tk
transgenic male mice.
Conclusions
The nuclear clearance and cytoplasmic retargeting of HSV1-
tk/GFP were achieved with different site-directed and N-
terminally truncated HSV1-tk/GFP mutants. The retargeted
HSV1-tk/GFPmutant proteins are expressed at higher levels
compared to the native HSV1-tk/GFP in bulk populations of
transduced cells due to the absence of nuclear toxicity. The
observed increase in total cellular enzymatic activity of the
mutant HSV1-tk/GFP variants compared to native HSV1-tk/
GFP expressed at the same protein level is probably due to
improved bioavailability of the retargeted mutant HSV1-tk/
GFP enzymes in the cytoplasm. Cytoplasmic retargeting of
mutant HSV1-tk/GFP is likely to facilitate reaction with
exogenous substrates and radiolabeled probes (e.g., FIAU),
with no significant change in enzyme kinetic properties. The
improved total cellular enzymatic activity of retargeted
HSV1-tk/GFP mutants confers higher levels of [131I]FIAU
accumulation in transduced subcutaneous tumor xenograft-
bearing rats, and this should result in a higher sensitivity of
these mutant HSV1-tk/GFP reporter systems.
References
[1] Bengel FM, Anton M, Avril N, Brill T, Nguyen N, Haubner R, Gleiter E,
Gansbacher B, and Schwaiger M (2000). Uptake of radiolabeled 2V-
fluoro-2V-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells
after adenoviral transfer of the herpesvirus thymidine kinase gene:
the cellular basis for cardiac gene imaging. Circulation 102, 948–50.
[2] Bhaumik S, and Gambhir SS (2002). Optical imaging of Renilla lucifer-
ase reporter gene expression in living mice. Proc Natl Acad Sci USA
99, 377–82.
[3] Black ME, Kokoris MS, and Sabo P (2001). Herpes simplex virus-1
thymidine kinase mutants created by semi-random sequence mutagen-
esis improve prodrug-mediated tumor cell killing. Cancer Res 61,
3022–26.
[4] Black ME, Rechtin TM, and Drake RR (1996). Effect on substrate bind-
ing of an alteration at the conserved aspartic acid-162 in herpes sim-
plex virus type 1 thymidine kinase. J Gen Virol 77 (Pt 7), 1521–27.
[5] Brown DG, Visse R, Sandhu G, Davies A, Rizkallah P, Melitz C, Sum-
mers W, and Sanderson MR (1995). Crystal structures of the thymidine
kinase from herpes simplex virus type-1 in complex with deoxythymi-
dine and ganciclovir. Nat Struct Biol 2, 876–81.
[6] Brust P, Haubner R, Friedrich A, Scheunemann M, Anton M, Koufaki
ON, Noll S, Noll B, Haberkorn U, Schackert G, Schackert HK, Avril N,
and Johannsen B (2001). Comparison of [18F]FHPG and [124/125I]FIAU
for imaging herpes simplex virus type 1 thymidine kinase gene expres-
sion. Eur J Nucl Med 28, 721–29.
[7] Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias
DA, and Tsien RY (2002). A monomeric red fluorescent protein. Proc
Natl Acad Sci USA 99, 7877–82.
[8] Champness JN, Bennett MS, Wien F, Visse R, Summers WC, Herde-
wijn P, de Clerq E, Ostrowski T, Jarvest RL, and Sanderson MR (1998).
Exploring the active site of herpes simplex virus type-1 thymidine kin-
ase by X-ray crystallography of complexes with aciclovir and other
ligands. Proteins 32, 350–61.
[9] Cohen JL, Boyer O, Salomon B, Onclerco R, Depetris D, Lejeune L,
Dubus-Bonnet V, Bruel S, Charlotte F, Mattei MG, and Klatzmann D
(1998). Fertile homozygous transgenic mice expressing a functional
truncated herpes simplex thymidine kinase delta TK gene. Transgenic
Res 7, 321–30.
[10] Contag CH, and Bachmann MH (2002). Advances in in vivo biolumines-
cence imaging of gene expression. Annu Rev Biomed Eng 4, 235–60.
[11] Contag CH, Jenkins D, Contag PR, and Negrin RS (2000). Use of
reporter genes for optical measurements of neoplastic disease in vivo.
Neoplasia 2, 41–52.
[12] Cowsill C, Southgate TD, Morrissey G, Dewey RA, Morelli AE, Mal-
eniak TC, Forrest Z, Klatzmann D, Wilkinson GW, Lowenstein PR,
and Castro MG (2000). Central nervous system toxicity of two adeno-
viral vectors encoding variants of the herpes simplex virus type 1 thy-
midine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Ther
7, 679–85.
[13] Degreve B, Esnouf R, De Clercq E, and Balzarini J (1999). Character-
ization of multiple nuclear localization signals in herpes simplex virus
type 1 thymidine kinase. Biochem Biophys Res Commun 264, 338–42.
[14] Degreve B, Johansson M, De Clercq E, Karlsson A, and Balzarini J
(1998). Differential intracellular compartmentalization of herpetic thymi-
dine kinases (TKs) in TK gene-transfected tumor cells: molecular char-
acterization of the nuclear localization signal of herpes simplex virus
type 1 TK. J Virol 72, 9535–43.
[15] Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn
R, Humm J, Larson S, Sadelain M, Blasberg R, and Gelovani Tjuvajev J
(2001). Imaging transcriptional regulation of p53-dependent genes with
positron emission tomography in vivo. Proc Natl Acad Sci USA 98,
9300–05.
[16] Dubrovin M, Ponomarev V, Beresten T, Matei C, Koutcher J, and Tju-
vajev J (2000). In Vivo 19F Nuclear Magnetic Resonance Measure-
HSV1-tk/GFP Reporter Gene Mutants Ponomarev et al. 253
Neoplasia . Vol. 5, No. 3, 2003
ments of Enhanced 5FU Conversion to Fluoronucleotides after UPRT
Gene Transduction. Abstract, 3rd Annual Meeting of the ASGT, Den-
ver, CO, May 31–June 4, 2000.
[17] Ellenberg J, Lippincott-Schwartz J, and Presley JF (1999). Dual-colour
imaging with GFP variants. Trends Cell Biol 9, 52–56.
[18] Falk MM, and Lauf U (2001). High resolution, fluorescence deconvolu-
tion microscopy and tagging with the autofluorescent tracers CFP,
GFP, and YFP to study the structural composition of gap junctions in
living cells. Microsc Res Tech 52, 251–62.
[19] Gallardo HF, Tan C, Ory D, and Sadelain M (1997). Recombinant
retroviruses pseudotyped with the vesicular stomatitis virus G glycopro-
tein mediate both stable gene transfer and pseudotransduction in hu-
man peripheral blood lymphocytes. Blood 90, 952–57.
[20] Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N,
Bauer E, Parrish C, MacLaren DC, Borghei AR, Green LA, Sharfstein S,
Berk AJ, Cherry SR, Phelps ME, and Herschman HR (1998). Imaging of
adenoviral-directed herpes simplex virus type 1 thymidine kinase report-
er gene expression in mice with radiolabeled ganciclovir. J Nucl Med 39,
2003–11.
[21] Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N,
Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Sadelain M,
Tjuvajev J, and Blasberg R (2000). Imaging transgene expression with
radionuclide imaging technologies. Neoplasia 2, 118–38.
[22] Green L, Yap C, Nguyen N, Barrio J, Namavari M, Satyamurthy N,
Phelps M, Sandgren E, Herschman H, and Gambhir S (2002). Indirect
monitoring of endogenous gene expression by positron emission to-
mography (PET) imaging of reporter gene expression in transgenic
mice. Mol Imaging Biol 4, 71–81.
[23] Haberkorn U (2001). Gene therapy with sodium/iodide symporter in
hepatocarcinoma. Exp Clin Endocrinol 1, 60–62.
[24] Hackman TDM, Balatoni J, Beresten T, Ponomarev V, Beattie B, Finn R,
Bornmann W, Blasberg R, and Gelovani Tjuvajev J (2002). Imaging ex-
pression of cytosine deaminase-herpes virus thymidine kinase fusion
gene (CD/TK) expression with [124I]FIAU and PET. Mol Imaging 1,
36–42.
[25] Hadjantonakis AK, and Nagy A (2001). The color of mice: in the light of
GFP-variant reporters. Histochem Cell Biol 115, 49–58.
[26] Jacobs A, Dubrovin M, Hewett J, Sena-Esteves M, Tan CW, Slack M,
Sadelain M, Breakefield XO, and Tjuvajev JG (1999). Functional coex-
pression of HSV-1 thymidine kinase and green fluorescent protein:
implications for noninvasive imaging of transgene expression. Neopla-
sia 1, 154–61.
[27] Kokoris MS, and Black ME (2002). Characterization of herpes simplex
virus type 1 thymidine kinase mutants engineered for improved ganci-
clovir or acyclovir activity. Protein Sci 11, 2267–72.
[28] Kokoris MS, Sabo P, Adman ET, and Black ME (1999). Enhancement
of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene
Ther 6, 1415–26.
[29] Kokoris MS, Sabo P, and Black ME (2000). In vitro evaluation of mutant
HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res 20,
959–63.
[30] Kussmann-Gerber S, Kuonen O, Folkers G, Pilger BD, and Scapozza L
(1998). Drug resistance of herpes simplex virus type 1-structural con-
siderations at the molecular level of the thymidine kinase. Eur J Bio-
chem 255, 472–81.
[31] Lalwani AK, Han JJ, Walsh BJ, Zolotukhin S, Muzyczka N, and Mhatre
AN (1997). Green fluorescent protein as a reporter for gene transfer
studies in the cochlea. Hear Res 114, 139–47.
[32] Levy JP, Muldoon RR, Zolotukhin S, and Link Jr, CJ 1996. Retroviral
transfer and expression of a humanized, red-shifted green fluorescent
protein gene into human tumor cells. Nat Biotechnol 14, 610–14.
[33] Liang Q, Satyamurthy N, Barrio JR, Toyokuni T, Phelps MP, Gambhir
SS, and Herschman HR (2001). Noninvasive, quantitative imaging in
living animals of a mutant dopamine D2 receptor reporter gene in which
ligand binding is uncoupled from signal transduction. Gene Ther 8,
1490–98.
[34] Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan
CE, Piwnica-Worms H, and Piwnica-Worms D (2002). Noninvasive
imaging of protein –protein interactions in living animals. Proc Natl
Acad Sci USA 99, 6961–66.
[35] Mathieu S, and El-Battari (2003). Monitoring E-selectin –mediated
adhesion using green and red fluorescent proteins. J Immunol Methods
272, 81–92.
[36] Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Born-
man W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, and
Tjuvajev JG (2001). Imaging TCR-dependent NFAT-mediated T-cell
activation with positron emission tomography in vivo. Neoplasia 3,
480–88.
[37] Ponomarev VDM, Beresten T, Balatoni J, Blasberg R, and Tjuvajev JG
(2000). Functional coexpression of HSV1-tk and GFP and generation of
mutants with different subcellular localization of TK/GFP fusion protein
for gene therapy of gliomas. J Nucl Med 41, 81.
[38] Ponomarev VDM, Serganova I, Ageyeva L, Beresten T, Sagomonyan
S, Balatoni J, Finn R, Blasberg R, and Gelovani Tjuvajev JG (2002).
Human Thymidine Kinase Type 2—A Novel Non-Immunogenic Report-
er Gene For Non-Invasive Imaging In Humans. AACR Meeting, Molec-
ular Imaging in Cancer, Orlando, FL, January 23–27, 2002.
[39] Ponomarev VSIALBT, Doubrovin M, and Gelovani Tjuvajev JG (2001).
Xanthine Phosphoribosyl Transferase and Red Fluorescent Protein Fu-
sion—A Novel Reporter Gene for Multi-Modality Imaging. Abstract, 9th
Annual Meeting of the ESGT, Antalya, Turkey, November 2–4, 2001.
[40] Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst
T, Blasberg RG, Tjuvajev JG, Chen SH, and Woo SL (2002). Tumor-
specific transcriptional targeting of suicide gene therapy. Gene Ther 9,
168–75.
[41] Ray P, Bauer E, Iyer M, Barrio JR, Satyamurthy N, Phelps ME, Hersch-
man HR, and Gambhir SS (2001). Monitoring gene therapy with report-
er gene imaging. Semin Nucl Med 31, 312–20.
[42] Rogers BE, Zinn KR, and Buchsbaum DJ (2000). Gene transfer strat-
egies for improving radiolabeled peptide imaging and therapy. Q J Nucl
Med 3, 208–23.
[43] Salomon B, Maury S, Loubiere L, Caruso M, Onclercq R, and Klatz-
mann D (1995). A truncated herpes simplex virus thymidine kinase
phosphorylates thymidine and nucleoside analogs and does not cause
sterility in transgenic mice. Mol Cell Biol 15, 5322–28.
[44] Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg
RG, Tjuvajev JG, and Ross BD (1999). Noninvasive quantitation of
cytosine deaminase transgene expression in human tumor xenografts
with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA
96, 9821–26.
[45] Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M,
Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J,
Humm J, Larson SM, Finn R, and Blasberg R (1998). Imaging herpes
virus thymidine kinase gene transfer and expression by positron emis-
sion tomography. Cancer Res 58, 4333–41.
[46] Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM,
Finn R, Bornmann W, Thaler H, Conti PS, and Blasberg RG (2002).
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and
FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 43,
1072–83.
[47] Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gans-
bacher B, and Blasberg RG (1995). Imaging the expression of trans-
fected genes in vivo. Cancer Res 55, 6126–32.
[48] Wild K, Bohner T, Aubry A, Folkers G, and Schulz GE (1995). The
three-dimensional structure of thymidine kinase from herpes simplex
virus type 1. FEBS Lett 368, 289–92.
[49] Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamur-
thy N, Goldman R, Herschman HR, Phelps ME, and Gambhir SS
(2001). Human pharmacokinetic and dosimetry studies of
[(18)F]FHBG: a reporter probe for imaging herpes simplex virus
type-1 thymidine kinase reporter gene expression. J Nucl Med 42,
1225–34.
254 HSV1-tk/GFP Reporter Gene Mutants Ponomarev et al.
Neoplasia . Vol. 5, No. 3, 2003
